DOCSLIB.ORG

E2017138 (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
E2017138 (PDF) History of Modern Biomedicine Research Group School of History, Queen Mary University of London Mile End Road, London E1 4NS website: www.histmodbiomed.org VIDEO INTERVIEW TRANSCRIPT Sanger, Gareth: transcript of a video interview (08-Dec-2016) Interviewer: Tilli Tansey Transcriber: Debra Gee Editors: Tilli Tansey, Apostolos Zarros Date of publication: 05-May-2017 Date and place of interview: 08-Dec-2016; Queen Mary University of London Publisher: Queen Mary University of London Collection: History of Modern Biomedicine Interviews (Digital Collection) Reference: e2017138 Number of pages: 10 DOI: 10.17636/01022654 Acknowledgments: The project management of Mr Adam Wilkinson and the technical support (filming and production) of Mr Alan Yabsley are gratefully acknowledged. The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey). Citation: Tansey E M (intvr); Tansey E M, Zarros A (eds) (2017) Sanger, Gareth: transcript of a video interview (08-Dec- 2016). History of Modern Biomedicine Interviews (Digital Collection), item e2017138. London: Queen Mary University of London. Related resources: items 2017139 - 2017152, History of Modern Biomedicine Interviews (Digital Collection) Note: Video interviews are conducted following standard oral history methodology, and have received ethical approval (reference QMREC 0642). Video interview transcripts are edited only for clarity and factual accuracy. Related material has been deposited in the Wellcome Library. © The Trustee of the Wellcome Trust, London, 2017 History of Modern Biomedicine Interviews (Digital Collection) - Sanger, G e2017138 | 2 Sanger, Gareth: transcript of a video interview (08-Dec-2016)* Biography: Professor Gareth Sanger BSc PhD DSc FBPhS FRSB (b. 1953) received his BSc and PhD degrees in physiology from the Universities of Newcastle and Manchester (1974 and 1977), later returning to Manchester to be awarded his DSc in 1998. He worked as a postdoctoral fellow at King’s College Hospital Medical School, London, where he was among the first to examine the functions of some of the newly discovered prostanoids on the human isolated gut. A move to industrial research led to his identification of a novel serotonin (5-HT) receptor-mediated function in the gut, later named by others as the 5-HT4 receptor. Parallel research led to the identification of the role of the 5-HT3 receptor in the mechanisms of emesis and to new drugs to treat severe emesis, for which he was jointly awarded the 1998 Discoverers Award by the Pharmaceutical Research and Manufacturers of America (PhRMA). Within industry he held various roles within the “discovery science” arm of the business, exploring multiple research areas and new drug targets, placing several novel compounds into development. In 2008 he was elected Fellow of the British Pharmacological Society (FBPhS), and in 2009 he joined Queen Mary, University of London as Professor of Neuropharmacology. He was elected Fellow of the Royal Society of Biology (FRSB) in 2013. His research focus is on the use of human gastrointestinal tissues for translational neuropharmacology, the consequences and mechanisms of advanced age on human bowel functions and on the mechanisms of disordered gastric movements during nausea. His first paper after establishing this new laboratory won a “highly commended” award from NC3Rs (National Centre for the Replacement, Refinement & Reduction of Animals in Research) for promoting a culture shift in the use of human tissues for functional research. He has published more than 150 peer-reviewed manuscripts, served on editorial boards, teaches on BSc, MSc and MBBS courses and sits on advisory boards for gastrointestinal (GI) research within the pharmaceutical industry. [1]. A CHILD BY THE COAST; STUDYING MARINE ZOOLOGY AT NEWCASTLE I had no intention of being a scientist. I just enjoyed life with a very open, simple, probably uncritical, unfocused mind. I lived in the country as a boy, it meant that I didn’t really associate with all my friends who lived in town, and did things that teenagers do, and I couldn’t, because we lived so far away. It meant that I spent my life with a great friend, mostly on the beach, fishing, swimming, always there. And I guess that helped nurture my enjoyment of beach life. I did biology projects on mussel beds, and one thing led to another I guess, and I wanted to continue enjoying that, hence an application to Newcastle University to study zoology, chosen in part because they had a great marine biology station and I thought, ‘That will be fun.’ I could imagine myself researching and understanding marine life, went to Newcastle, felt liberated because I no longer had to do subjects at A level like physics, which I couldn’t do very well. And yes, there was a pleasure in learning; there was a liberation. Loved zoology, loved the discovery of the coelacanth at the time, the fossil now alive. It was a great time. But I had to do other courses. I had to do physical sciences, which I didn’t really enjoy, and I had to pick another subject, chose physiology, which at school I’d never heard of before. By the end of the year realised I loved zoology, but kind of didn’t know where that would go. But a feeling inside me told me that physiology was a bit more hardcore science, a bit more directed and might lead to different and better things. And I had no idea what that meant. * Interview conducted by Professor Tilli Tansey, for the History of Modern Biomedicine Research Group, 08 December 2016, in the School of History, Queen Mary University of London. Transcribed by Mrs Debra Gee, and edited by Professor Tilli Tansey and Dr Apostolos Zarros. History of Modern Biomedicine Interviews (Digital Collection) - Sanger, G e2017138 | 3 [2]. FROM ZOOLOGY TO PHYSIOLOGY, STUDYING THE GASTROINTESTINAL SYSTEM So at the end of my first year at university, I loved the zoology but there was a feeling inside me that thought, ‘I’d like that as a hobby. I don’t quite see what I can do with it.’ Whereas physiology spoke to me in some sort of way, maybe more hardcore science, maybe more of a clearer direction, I wasn’t sure. Went to see my then zoology tutor, Dr Panshen who said, ‘Look, whatever you choose will be right, because you’ll never know what you gave up.’ The wisest advice I’ve probably ever received, and I’ve said it to many people since. So I went to physiology, which I’d never heard of at school, no idea what that was. And spent a couple of enjoyable years with a small group, I think there were about seven of us doing the degree, so it was very close. We all became great friends and ended up with our degrees. It was a University Department that specialised a lot in gastrointestinal science. Professor Harper used to run it, he was a joint discoverer of cholecystokinin. He retired, Professor Eric Blair took over, he did a lot of work on gastric secretion, and a lot of colleagues were there doing that, so my student project was on gastric secretion in anaesthetised cats, which you’d never do again. And I guess it became by default a career path for me to stay in GI. I was lucky enough to spot a PhD-student vacancy in Manchester, so without any planning, without any thought, I applied and I was lucky to be accepted, and there I was in Manchester. [3]. BECOMING A PHARMACOLOGIST: PROSTAGLANDIN RESEARCH AT KING’S COLLEGE LONDON So the PhD in my view was ordinary, and by the end of that I believed I needed training. I’d picked up papers by Alan Bennett, then in King’s College Hospital, Surgery Department there, who wrote papers that kind of spoke to me as well. They were good papers, but they seemed to push the science a little bit forward in a place that I thought was creative, and I liked that for some reason. So I went down and saw Alan. We talked and a little later, and I said, ‘Is there a possibility of working with you?’ And he eventually came back to me and said, ‘Yes, I can put the money together on provision you get your PhD first.’ So I then promptly made him my external examiner, and got the PhD, and joined Alan. Of course my degree was physiology, my PhD was in the Physiology Department, but I was doing pharmacology. I was doing ligand receptor interaction studies in effect. Alan was a pharmacist but PhD pharmacology, and effectively trained me. So I would come into work and you had to walk past his office to get past the lab, and I eventually learnt to kind of creep by his office a little bit because once he realised I didn’t know pharmacology and I needed training. So he would start leaping out of his office and saying, ‘Define me a pA2.’ And the first time I thought, ‘pA2, what on earth is that?’ So I screwed that up completely. And this would go on until eventually I could define a pA2 verbatim; I’d learnt it. I knew a pA2. Then he’d move onto pD2, and eventually I kind of learnt. He would, which is no different to my father, going down to breakfast he’d say, ‘What’s six 8s?’ ‘48.’ I’d know that so well. [4]. BECOMING A PHARMACOLOGIST: THE BRITISH PHARMACOLOGICAL SOCIETY So, eventually, he would get me to prepare a talk, ten minute talk, for the British Pharmacological Society and I would prepare the talk.
Load more

Recommended publications
  • Miner, Wesley: Transcript of an Audio Interview (15-Jul-2016)
    History of Modern Biomedicine Research Group School of History, Queen Mary University of London Mile End Road, London E1 4NS website: www.histmodbiomed.org AUDIO INTERVIEW TRANSCRIPT Miner, Wesley: transcript of an audio interview (15-Jul-2016) Interviewer: Tilli Tansey Transcriber: Debra Gee Editors: Tilli Tansey, Adam Wilkinson Date of publication: 14-Oct-2016 Date and place of interview: 15-Jul-2016; Queen Mary University of London Publisher: Queen Mary University of London Collection: History of Modern Biomedicine Interviews (Digital Collection) Reference: e2016094 Number of pages: 27 DOI: 10.17636/01015867 Acknowledgments: The technical support of Mr Alan Yabsley is gratefully acknowledged. The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey). Citation: Tansey E M (intvr); Tansey E M, Wilkinson A (eds) (2016) Miner, Wesley: transcript of an audio interview (15- Jul-2016). History of Modern Biomedicine Interviews (Digital Collection), item e2016094. London: Queen Mary University of London. Note: Audio interviews are conducted following standard oral history methodology, and have received ethical approval (reference QMREC 0642). Related material has been deposited in the Wellcome Library. © The Trustee of the Wellcome Trust, London, 2016 History of Modern Biomedicine Interviews (Digital Collection) - Miner, W e2016094 | 2 Miner, Wesley: transcript of an audio interview (15-Jul-2016)* Biography: Mr Wesley Miner BSc (b. 1948) is a graduate in physiology from the University of Edinburgh. From 1982 to 1986 he worked at Beecham Pharmaceuticals (GlaxoSmithKline since 2000) with Gareth Sanger.
    [Show full text]
  • Supportive Care for Chemotherapy Induced Nausea & Vomiting
    Supportive Care for Chemotherapy Induced Nausea & Vomiting (CINV): The next steps in improving outcomes Dr Richard Berman FRCP Supportive Care Physician Honorary Senior Lecturer in Cancer Sciences The Christie NHS Foundation Trust This session is sponsored by TESARO UK who selected the speaker and reviewed the slides, which may contain promotional content Funding Source and Conflicts of Interest • Consultations: Grunenthal, Astra Zeneca, Chugai • Honoraria for lectures: Tesaro, Kyowa Kirin, Chugai The content and interpretation of this presentation are the views and comment of the speaker and not of Tesaro. The Christie NHS Foundation Trust Supportive care [in cancer] is the prevention and management of the adverse effects of cancer and cancer treatment The landscape of cancer is changing More and more people are living longer with cancer Proactive supportive care can improve survival 1. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer, Temel JS et al, N Engl J Med 2010; 363:733- 742 August 19, 2010. 2. Palliative and Supportive Care: Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial - Marie A. Bakitas, Journal of Clinical Oncology May 1, 2015:1438-1445; published online on March 23, 2015; DOI:10.1200/JCO.2014.58.6362 3. Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non–Small-Cell Lung Cancer; Joseph A. Greer, JCO; Feb 1 2012, vol 30, no 4, 394-400) 4. Overall Survival
    [Show full text]
  • The Discovery, Use and Impact of Platinum Salts As Chemotherapy Agents for Cancer
    THE DISCOVERY, USE AND IMPACT OF PLATINUM SALTS AS CHEMOTHERAPY AGENTS FOR CANCER The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 4 April 2006 Edited by D A Christie and E M Tansey Volume 30 2007 ©The Trustee of the Wellcome Trust, London, 2007 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2007 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 112 7 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Christie D A, Tansey E M. (eds) (2007) The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Twentieth Century Medicine, vol. 30. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and D A Christie ix Introduction Matti Aapro xxiii Transcript Edited by D A Christie and E M Tansey 1 Appendix 1 Poem by Professor Sir Kenneth Calman, In Praise of Methotrexate 78 Appendix 2 Structures of some 5HT3 receptor antagonists 82 Appendix 3 Components of the emetic reflex 83 References 84 Biographical notes 98 Glossary 106 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 Platinum (II) and platinum (IV) ions dictate different coordination numbers and geometries on a set of surrounding ligands. Figure provided by Professor Andrew Thomson.
    [Show full text]
  • The Discovery, Use and Impact of Platinum Salts As Chemotherapy Agents for Cancer
    THE DISCOVERY, USE AND IMPACT OF PLATINUM SALTS AS CHEMOTHERAPY AGENTS FOR CANCER The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 4 April 2006 Edited by D A Christie and E M Tansey Volume 30 2007 ©The Trustee of the Wellcome Trust, London, 2007 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2007 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 112 7 All volumes are freely available online following the links to Publications/Wellcome Witnesses at www.ucl.ac.uk/histmed Technology Transfer in Britain: The case of monoclonal antibodies; Self and Non-self: A history of autoimmunity; Endogenous Opiates; The Committee on Safety of Drugs • Making the Human Body Transparent: The impact of NMR and MRI; Research in General Practice; Drugs in Psychiatric Practice; The MRC Common Cold Unit • Early Heart Transplant Surgery in the UK • Haemophilia: Recent history of clinical management • Looking at the Unborn: Historical aspects of obstetric ultrasound • Post Penicillin Antibiotics: From acceptance to resistance? • Clinical Research in Britain, 1950–1980 • Intestinal Absorption • Origins of Neonatal Intensive Care in the UK • British Contributions to Medical Research and Education in Africa after the Second World War • Childhood Asthma and Beyond • Maternal Care • Population-based Research in South Wales: The MRC Pneumoconiosis Research Unit and the
    [Show full text]
  • Drugs Affecting 5-HT Systems
    DRUGS AFFECTING 5-HT SYSTEMS The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary, University of London, on 20 November 2012 Edited by C Overy and E M Tansey Volume 47 2013 ©The Trustee of the Wellcome Trust, London, 2013 First published by Queen Mary, University of London, 2013 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 90223 887 9 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/ wellcome_witnesses/ Please cite as: Overy C, Tansey E M. (eds) (2013) Drugs Affecting 5-HT Systems. Wellcome Witnesses to Contemporary Medicine, vol. 47. London: Queen Mary, University of London. CONTENTS What is a Witness Seminar v Acknowledgements E M Tansey and C Overy vii Illustrations and credits ix Abbreviations xi Ancillary guides xiii Introduction E M Tansey xv Transcript Edited by C Overy and E M Tansey 1 Appendix 1 Pioneering research by SmithKline Beecham: 5-HT3 receptor antagonism and anti-emetic activity Professor Gareth Sanger 139 Biographical notes 141 References 159 Index 187 Witness Seminars: Meetings and Publications 203 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories. The meeting is recorded, transcribed and edited for publication. This format was first devised and used by the Wellcome Trust’s History of Twentieth Century Medicine Group in 1993 to address issues associated with the discovery of monoclonal antibodies.
    [Show full text]
  • Investigating the Effect of Emetic and Aversive Compounds on Dictyostelium Identifies a Novel Non-Sentient Model for Bitter Tastant Research
    Investigating the effect of emetic and aversive compounds on Dictyostelium identifies a novel non-sentient model for bitter tastant research Steven Jann Robery Research thesis submitted for the degree of Doctor of Philosophy at Royal Holloway University of London in July 2013 Declaration of Authorship I, Steven Robery, hereby declare that this thesis and the work presented in it is entirely my own. Where I have consulted the work of others, this is always clearly stated. Signed: Date: 2 Acknowledgements First and foremost, I would like to thank my supervisors, Professor Robin Williams and Professor Paul Andrews. I would like to thank Robin for providing me with the support and direction he has given me over the past few years, as well as teaching me to critique my own work to make me a better scientist. I would like to thank Paul for providing me with support, advice and passion throughout my PhD. Your meetings were always inspirational. I would also like to thank my laboratory colleagues for all of the help, support and banter whilst I have been at Royal Holloway. Secondly, I would like to thank my funding body, Universities Federation for Animal Welfare. Without you I would not have been given a PhD and been able to undertake this exciting project, nor would I have been able to contribute to the world of science in the way that I have. I would also like to thank my friends and family for all of the support you have given me over the years. In particular I would like to thank my girlfriend Annabelle, for putting up with me and for providing me with laughs and generally being there for me when I needed her to be.
    [Show full text]
  • Psychophysiological Markers and the Brain Processing of Visual Motion Induced Nausea in Healthy Humans
    Psychophysiological markers and the brain processing of visual motion induced nausea in healthy humans Kee Seong Ng Thesis submitted for the Degree of Doctor of Philosophy Barts & The London School of Medicine & Dentistry, Queen Mary University of London November 2012 1 TABLE OF CONTENTS ABSTRACT ........................................................................................................................................... 19 ABBREVIATIONS ................................................................................................................................. 21 CHAPTER 1 .......................................................................................................................................... 24 1.1 DEFINITIONS ........................................................................................................................................ 26 1.2 ASSESSING NAUSEA .............................................................................................................................. 27 1.3 IMPACT OF NAUSEA .............................................................................................................................. 28 1.4 NAUSEA THE NEGLECTED SYMPTOM ........................................................................................................ 29 1.5 PATHWAYS OF NAUSEA AND VOMITING .................................................................................................... 30 1.5.1 Potential cortical pathways of nausea ....................................................................................
    [Show full text]